These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37614985)

  • 1. Suppression of antitumor cytokine IL‑24 by PRG4 and PAI‑1 may promote myxoid liposarcoma cell survival.
    Oikawa K; Kuroda M; Ehata S
    Biomed Rep; 2023 Sep; 19(3):60. PubMed ID: 37614985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRG4 expression in myxoid liposarcoma maintains tumor cell growth through suppression of an antitumor cytokine IL-24.
    Oikawa K; Mizusaki A; Takanashi M; Ozaki T; Sato F; Kuroda M; Muragaki Y
    Biochem Biophys Res Commun; 2017 Mar; 485(1):209-214. PubMed ID: 28192118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma.
    Borjigin N; Ohno S; Wu W; Tanaka M; Suzuki R; Fujita K; Takanashi M; Oikawa K; Goto T; Motoi T; Kosaka T; Yamamoto K; Kuroda M
    Biochem Biophys Res Commun; 2012 Oct; 427(2):355-60. PubMed ID: 22995304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of MKL1 promotes adipocytic differentiation and reduces the proliferation of myxoid liposarcoma cells.
    Kamikawa Y; Yokota K; Oikawa K; Sato F; Muragaki Y
    Oncol Lett; 2020 Dec; 20(6):369. PubMed ID: 33154767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression.
    Oikawa K; Tanaka M; Itoh S; Takanashi M; Ozaki T; Muragaki Y; Kuroda M
    Br J Cancer; 2012 Jun; 106(12):1976-9. PubMed ID: 22588557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in myxoid liposarcoma: Clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma.
    Suzuki K; Matsui Y; Hashimoto N; Naka N; Araki N; Kimura T; Yoshikawa H; Ueda T
    Oncol Lett; 2012 Feb; 3(2):293-296. PubMed ID: 22740897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
    Antonescu CR; Tschernyavsky SJ; Decuseara R; Leung DH; Woodruff JM; Brennan MF; Bridge JA; Neff JR; Goldblum JR; Ladanyi M
    Clin Cancer Res; 2001 Dec; 7(12):3977-87. PubMed ID: 11751490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of FUS-CHOP in Myxoid Liposarcoma via miR-486/CDK4 Axis.
    Wu H; Xia L; Xu H
    Biochem Genet; 2022 Jun; 60(3):1095-1106. PubMed ID: 34792704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
    Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.
    Kuroda M; Ishida T; Horiuchi H; Kida N; Uozaki H; Takeuchi H; Tsuji K; Imamura T; Mori S; Machinami R
    Am J Pathol; 1995 Nov; 147(5):1221-7. PubMed ID: 7485386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma.
    Kerr LT; Donoghue JF; Wilding AL; Johns TG
    Sarcoma; 2016; 2016():3484673. PubMed ID: 27822137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting WEE1 Kinase Activity as FUS::DDIT3-Dependent Therapeutic Vulnerability in Myxoid Liposarcoma.
    Heinst L; Lee KS; Berthold R; Isfort I; Wosnig S; Kuntze A; Hafner S; Altvater B; Rossig C; Åman P; Wardelmann E; Scholl C; Hartmann W; Fröhling S; Trautmann M
    Clin Cancer Res; 2024 Nov; 30(21):4974-4986. PubMed ID: 39207225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas.
    Huang HY; Antonescu CR
    Ultrastruct Pathol; 2003; 27(4):217-26. PubMed ID: 12907366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function.
    Adelmant G; Gilbert JD; Freytag SO
    J Biol Chem; 1998 Jun; 273(25):15574-81. PubMed ID: 9624148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristic sequence motifs at the breakpoints of the hybrid genes FUS/CHOP, EWS/CHOP and FUS/ERG in myxoid liposarcoma and acute myeloid leukemia.
    Panagopoulos I; Lassen C; Isaksson M; Mitelman F; Mandahl N; Aman P
    Oncogene; 1997 Sep; 15(11):1357-62. PubMed ID: 9315104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells.
    Rapp TB; Yang L; Conrad EU; Mandahl N; Chansky HA
    J Orthop Res; 2002 Jul; 20(4):723-9. PubMed ID: 12168660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein.
    Kuroda M; Ishida T; Takanashi M; Satoh M; Machinami R; Watanabe T
    Am J Pathol; 1997 Sep; 151(3):735-44. PubMed ID: 9284822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways.
    Nabeshima A; Matsumoto Y; Fukushi J; Iura K; Matsunobu T; Endo M; Fujiwara T; Iida K; Fujiwara Y; Hatano M; Yokoyama N; Fukushima S; Oda Y; Iwamoto Y
    Br J Cancer; 2015 Feb; 112(3):547-55. PubMed ID: 25562433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.